Bank of New York Mellon Corp Sells 865,743 Shares of Health Catalyst, Inc. (NASDAQ:HCAT)

Bank of New York Mellon Corp cut its position in Health Catalyst, Inc. (NASDAQ:HCAT - Free Report) by 37.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,437,006 shares of the company's stock after selling 865,743 shares during the period. Bank of New York Mellon Corp owned 2.36% of Health Catalyst worth $10,160,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Quest Partners LLC acquired a new stake in shares of Health Catalyst in the 3rd quarter worth about $34,000. Stoneridge Investment Partners LLC bought a new stake in shares of Health Catalyst in the 4th quarter worth approximately $77,000. Quadrature Capital Ltd purchased a new position in shares of Health Catalyst during the 3rd quarter valued at $84,000. Intech Investment Management LLC bought a new position in Health Catalyst during the third quarter worth about $145,000. Finally, Dynamic Advisor Solutions LLC bought a new position in Health Catalyst in the 4th quarter worth approximately $180,000. 85.00% of the stock is owned by institutional investors.

Analyst Ratings Changes

HCAT has been the subject of a number of analyst reports. Wells Fargo & Company cut their price objective on shares of Health Catalyst from $13.00 to $10.00 and set an "overweight" rating for the company in a research report on Tuesday, January 21st. Piper Sandler lowered their price target on Health Catalyst from $12.00 to $8.00 and set an "overweight" rating on the stock in a research report on Tuesday, February 11th. KeyCorp upgraded Health Catalyst from a "sector weight" rating to an "overweight" rating and set a $9.00 price objective for the company in a report on Wednesday, January 8th. Citigroup decreased their price objective on Health Catalyst from $10.50 to $10.00 and set a "buy" rating on the stock in a report on Friday, January 10th. Finally, Stifel Nicolaus cut their target price on Health Catalyst from $10.00 to $5.00 and set a "hold" rating for the company in a research note on Thursday, February 27th. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, Health Catalyst currently has a consensus rating of "Moderate Buy" and a consensus price target of $9.27.

Remove Ads

Health Catalyst Trading Up 7.5 %

Shares of Health Catalyst stock traded up $0.31 during trading on Monday, reaching $4.45. 673,160 shares of the stock were exchanged, compared to its average volume of 599,915. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32. The firm has a market cap of $312.44 million, a price-to-earnings ratio of -3.30 and a beta of 1.41. Health Catalyst, Inc. has a 1 year low of $3.76 and a 1 year high of $9.24. The stock's fifty day moving average is $5.43 and its 200 day moving average is $7.06.

Insiders Place Their Bets

In other Health Catalyst news, COO Daniel Lesueur sold 16,902 shares of the company's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $4.52, for a total value of $76,397.04. Following the completion of the transaction, the chief operating officer now directly owns 216,250 shares in the company, valued at approximately $977,450. This represents a 7.25 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Duncan Gallagher sold 4,500 shares of Health Catalyst stock in a transaction dated Monday, December 30th. The shares were sold at an average price of $6.93, for a total transaction of $31,185.00. Following the sale, the director now directly owns 69,938 shares in the company, valued at $484,670.34. The trade was a 6.05 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 65,530 shares of company stock worth $362,167. 2.50% of the stock is currently owned by company insiders.

Health Catalyst Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.